Is Decibel Therapeutics, Inc. (DBTX) a Buy, Sell, or Hold?
NASDAQ : DBTX
Decibel Therapeutics, Inc.
$4.91 USD
-$0.04 (-0.81%)
- Volume
- 1.06M
- Average Volume
- 247.44K
- Market Capitalization
- $123.37M
- P/E Ratio
- -1.95
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $5.40
- Year Low
- $1.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.81
Company Overview
NASDAQ
Laurence E. Reid
Biotechnology
Healthcare
DBTX
68
US
USD
Liquidity Metrics
0.17
4.81
4.81
1.54
0.00
Sales & Valuation
-$
0.00
1.50
-2.15
-2.30
Profitability
-$2.52
-$63M
0.00%
0.00%
-56.38%
-51.07%
P/E Metrics
-1.95
0.39
0.39
Analyst Price Target & Rating
0/5
7 Analysts
%
Financial Health Scores
-4.29
2/9
$53.87M
$94.39M
$41.08M
-$62.83M
Key Metrics (TTM)
$102.82M
0.00
-1.71
4.81
-56.38%
-61.19%
-51.41%
-46.49%
0 days
Company Executives
| Name | Title |
|---|---|
| Laurence E. Reid | Pres & Chief Executive Officer |
Poll Results
No votes yet today — be the first to share your view!
About Decibel Therapeutics, Inc. (NASDAQ:DBTX) Stock
Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm dedicated to pioneering innovative therapies for a range of hearing and balance impairments. Their research and development efforts are concentrated across three primary therapeutic avenues: 1. Gene Therapies for Congenital, Monogenic Hearing Loss: These programs aim to re-establish functional cellular activity within the cochlea, thereby counteracting hearing deficiencies stemming from single gene mutations. 2. Gene Therapies for Hair Cell Regeneration: This pipeline focuses on replenishing lost hair cells in the inner ear to alleviate acquired hearing and balance conditions. 3. Otoprotection Therapeutic: Currently in clinical development, this therapeutic is designed to safeguard cancer patients from hearing loss in ... duced by cisplatin chemotherapy. A flagship gene therapy candidate, DB-OTO, is being developed to restore auditory function in individuals suffering from profound hearing loss linked to mutations in the otoferlin gene. The company is also advancing several other programs, including DB-ATO and AAV.201, gene therapies intended to regenerate lost vestibular hair cells and thus re-establish balance in patients with bilateral vestibulopathy. DB-020 is undergoing Phase 1b clinical trials for the prevention of hearing loss caused by cisplatin. Further gene therapies in development include AAV.103 for individuals with a gap junction beta-2 (GJB2) deficiency, AAV.104 for those with a stereocilin (STRC) deficiency, and a cochlear hair cell regeneration program that employs AAV-based gene therapy to convert supporting cells into functional outer hair cells using cell-selective reprogramming factors. Decibel Therapeutics maintains a strategic alliance with Regeneron Pharmaceuticals, Inc., specifically for co-developing gene therapies addressing monogenic forms of inherited hearing loss. Established in 2013 and initially known as Hearing Inc., the company rebranded as Decibel Therapeutics, Inc. in April 2014. Its operations are headquartered in Boston, Massachusetts.
Frequently Asked Questions
-
What is the current Decibel Therapeutics, Inc. (DBTX) stock price?
-
Decibel Therapeutics, Inc.(NASDAQ:DBTX) stock price is $4.91 in the last trading session. During the trading session, DBTX stock reached the peak price of $5.4 while $1.61 was the lowest point it dropped to. The percentage change in DBTX stock occurred in the recent session was --0.81% while the dollar amount for the price change in DBTX stock was -$0.04.
-
DBTX's industry and sector of operation?
-
The NASDAQ listed DBTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DBTX?
-
Laurence E. Reid | Pres & Chief Executive Officer
|
|
|
| -
How many employees does DBTX have?
-
Number of DBTX employees currently stands at 68. DBTX operates from 1325 Boylston Street, Boston, MA 02215, US.
-
Link for DBTX official website?
-
Official Website of DBTX is: https://www.decibeltx.com
-
How do I contact DBTX?
-
DBTX could be contacted at phone #617 370 8701 and can also be accessed through its website. DBTX operates from 1325 Boylston Street, Boston, MA 02215, US.
-
How many shares of DBTX are traded daily?
-
The average number of DBTX shares traded daily for last 3 months was 247.44K.
-
What is the market cap of DBTX currently?
-
The market value of DBTX currently stands at $123.37M with its latest stock price at $4.91